Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Clasificación en acciones #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Precio por acción
$0.04443294
Capitalización bursátil
$13.65M
Cambio (1 día)
0.00%
Cambio (1 año)
-32.53%
País
AU
Comercio Noxopharm Limited (NOX)

Categoría

Healthcare
Ganancias de Noxopharm Limited (NOX)
Ganancias en Jun 2026 TTM: $-4.15M
Secondo gli ultimi rapporti finanziari di Noxopharm Limited, gli utili attuali della società sono $-4.15M. Nel 2024, la società ha registrato un utile di $-3.99M, un aumento con respecto a agli utili del 2023, che erano di $-14.02M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Noxopharm Limited desde 2016 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-4.15M 29.05%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -127,225.42%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 74,296.89%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 96,690.59%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -47,110.79%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH